Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer

Eur Urol. 2017 Mar;71(3):476-482. doi: 10.1016/j.eururo.2016.05.017. Epub 2016 May 24.

Abstract

Background: Primary robot-assisted retroperitoneal lymph node dissection (R-RPLND) has been studied as an alternative to open RPLND in single-institution series for patients with low-stage nonseminomatous germ cell tumors (NSGCT).

Objective: To evaluate a multicenter series of primary R-RPLND for low-stage NSGCT.

Design, setting, and participants: Between 2011 and 2015, 47 patients underwent primary R-RPLND at four centers for Clinical Stage (CS) I-IIA NSGCT.

Surgical procedure: R-RPLND was performed using the da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA, USA).

Outcome measurements and statistical analysis: Data were collected regarding patient demographics, primary tumor characteristics, pathologic findings, and clinical outcomes.

Results and limitations: Forty-two patients (89%) were CS I and five (11%) were CS IIA. The median operative time was 235min (interquartile range [IQR]: 214-258min), estimated blood loss was 50ml (IQR: 50-100ml), node count was 26 (IQR: 18-32), and length of stay was 1 d. There were two intraoperative complications (4%), four early postoperative complications (9%), no late complications, and the rate of antegrade ejaculation was 100%. Of the eight patients (17%) with positive nodes (seven pN1and one pN2), five (62%) received adjuvant chemotherapy. The one recurrence was out of template in the pelvis after adjuvant chemotherapy (resected teratoma). The median follow-up was 16 mo and the 2-yr recurrence-free survival rate was 97% (95% confidence interval: 82-100%). Limitations include retrospective design and limited follow-up.

Conclusions: Our multicenter experience supports R-RPLND as a potential option at experienced centers in select patients with low-stage NSGCT. Informal comparison to open and laparoscopic series suggests R-RPLND has an acceptably low morbidity profile, but oncologic efficacy evaluation requires further evaluation.

Patient summary: We examined outcomes after robot-assisted retroperitoneal lymph node dissection for patients with low-stage nonseminomatous testicular cancer with our data suggesting the robotic approach has acceptable morbidity and early oncologic outcomes.

Keywords: Complications; Lymph node excision; Nonseminomatous germ cell tumor; Testicular neoplasms; Treatment outcome.

MeSH terms

  • Adult
  • Blood Loss, Surgical
  • Humans
  • Length of Stay
  • Lymph Node Excision / methods*
  • Male
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / surgery*
  • Operative Time
  • Retroperitoneal Space / surgery*
  • Retrospective Studies
  • Robotic Surgical Procedures / methods*
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / surgery*

Supplementary concepts

  • Nonseminomatous germ cell tumor